MedImmune

MedImmune was a United States biopharmaceutical company whose origins lay in Molecular Vaccines, Inc., founded in 1988 by Wayne T. Hockmeyer, David Mott, and James Young. The company changed its name to MedImmune in 1989 and developed a business centered on biologic medicines, vaccines, and antibody-based therapies. Its most commercially important products were Synagis, a monoclonal antibody used to help prevent serious respiratory syncytial virus infections in certain high-risk infants, and FluMist, a live attenuated influenza vaccine administered as a nasal spray rather than an injection. The company expanded through acquisitions and research partnerships. In 2002, it acquired Aviron, gaining control of FluMist and its associated nasal-vaccine technology. FluMist received United States regulatory approval in 2003 and was introduced commercially in 2004. Its early commercial performance was constrained by an initially narrow approved population, the practical difficulties of storing the frozen product, and lower-than-expected demand. A later formulation and indication expansion improved the product's usability and market reach. In 2007, the U.S. Food and Drug Administration approved the vaccine for children aged two years and older, subject to applicable labeling and public-health guidance. AstraZeneca agreed in April 2007 to acquire MedImmune in an all-cash transaction and completed the purchase in June of that year. The reported transaction value was approximately $15.2 billion, with the acquisition intended to strengthen AstraZeneca's biologics pipeline. AstraZeneca combined MedImmune with Cambridge Antibody Technology, acquired in 2006, and used MedImmune as the name of its enlarged biologics research and development organization. The organization maintained important operations in Gaithersburg, Maryland, while also having activities in Cambridge, England, and Mountain View, California. During the AstraZeneca period, MedImmune worked across respiratory disease, immunology, oncology, and infectious disease. Its research portfolio included antibody and biologic candidates such as durvalumab, tremelimumab, moxetumomab pasudotox, benralizumab, tralokinumab, anifrolumab, and nirsevimab. Some later became AstraZeneca products or were developed with partners, while others did not become marketed medicines under the MedImmune name. The company also contributed to pandemic and influenza preparedness. It participated in an NIH Phase 1 study of an intranasal H5N1 vaccine candidate in 2007 and received a U.S. Department of Health and Human Services contract in 2009 to continue seasonal FluMist production and develop a vaccine against the novel H1N1 influenza strain. The FDA authorized MedImmune's intranasal H1N1 vaccine in September 2009. On February 14, 2019, AstraZeneca announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca. MedImmune therefore remains historically significant as an AstraZeneca-originated biopharmaceutical research and development organization, but it is no longer an active standalone public-facing brand.

MedImmune began in 1988 as Molecular Vaccines, Inc., established by Wayne T. Hockmeyer, David Mott, and James Young. The company adopted the MedImmune name in 1989 and developed a specialization in vaccines and biologic therapies. Its corporate development reflected the biotechnology industry's movement from platform research toward regulated, commercial products. A major early expansion came in 2002, when MedImmune acquired Aviron for approximately $1.5 billion. The transaction brought FluMist into MedImmune's portfolio. FluMist was designed as a live attenuated influenza vaccine delivered through the nose. It received U.S. approval in 2003 and entered the market in 2004. The product's initial commercial trajectory was difficult: its original approval covered healthy people aged five through 49, excluding many young children, and its frozen presentation created storage challenges for medical practices. Subsequent regulatory and product developments broadened its practical use. In 2007, the FDA approved FluMist for children aged two and older under the relevant product labeling. Synagis became MedImmune's principal commercial product. The medicine, whose active ingredient is palivizumab, was used to reduce the risk of serious respiratory syncytial virus disease in specified high-risk infants and young children. According to the cited historical material, Synagis generated most of MedImmune's 2005 revenue, illustrating how strongly the company depended on a small number of specialized biologic products while continuing to invest in its pipeline. AstraZeneca announced its agreement to buy MedImmune on April 23, 2007, and completed the acquisition on June 19, 2007. The all-cash purchase was reported at approximately $15.2 billion. Contemporary commentary questioned whether AstraZeneca had paid too much, but the strategic rationale was to obtain MedImmune's development capabilities and biologics portfolio. AstraZeneca subsequently combined MedImmune with Cambridge Antibody Technology, which it had acquired in 2006, and presented the enlarged biologics operation to investors in December 2007. Following the acquisition, the MedImmune organization worked on a broad pipeline spanning asthma, chronic obstructive pulmonary disease, lupus, oncology, and infectious diseases. Named development programs included the checkpoint inhibitors durvalumab and tremelimumab; the anti-CD22 therapy moxetumomab pasudotox; benralizumab for eosinophilic disease; tralokinumab; anifrolumab; and nirsevimab, an antibody directed at respiratory syncytial virus. Development ownership, approval status, and commercialization arrangements varied by program, and not every candidate became a marketed MedImmune product. MedImmune also participated in influenza preparedness. In 2007, the National Institutes of Health began enrolling participants in a Phase 1 study of an H5N1 vaccine candidate based on the company's live attenuated intranasal technology. During the 2009 H1N1 outbreak, the company worked with the U.S. Department of Health and Human Services under a reported $90 million contract covering seasonal FluMist production and development of a strain-specific vaccine. The FDA approved MedImmune's intranasal H1N1 vaccine in September 2009. On February 14, 2019, AstraZeneca announced that it would retire MedImmune branding and use the AstraZeneca name instead. This ended MedImmune's life as a distinct external brand, although capabilities, products, research programs, and personnel could continue within AstraZeneca's wider organization. The historical MedImmune entity is therefore best understood as an acquired biotechnology company and former AstraZeneca biologics brand rather than as an independent current pharmaceutical corporation.

1. 2019MedImmune branding is discontinued

   AstraZeneca announces that the MedImmune name and branding will be replaced by AstraZeneca branding.

   Source
2. 2009H1N1 vaccine authorization

   The FDA approves MedImmune's intranasal vaccine for novel H1N1 influenza.

   Source
3. 2007AstraZeneca acquisition closes

   AstraZeneca completes its approximately $15.2 billion acquisition of MedImmune.

   Source
4. 2007FluMist indication expands

   The FDA approves FluMist for children aged two years and older under the applicable labeling.

   Source
5. 2004FluMist commercial introduction

   FluMist is introduced commercially in the United States.

   Source
6. 2003FluMist receives U.S. approval

   The nasal influenza vaccine receives initial U.S. regulatory approval.

   Source
7. 2002Aviron acquisition

   MedImmune acquires Aviron, gaining FluMist and related nasal-vaccine technology.

   Source
8. 1989Company adopts the MedImmune name

   Molecular Vaccines changes its corporate name to MedImmune, Inc.

   Source
9. 1988Molecular Vaccines is founded

   Wayne T. Hockmeyer, David Mott, and James Young establish Molecular Vaccines, Inc.

   Source

Biopharmaceutical research and commercialization focused on biologic medicines, vaccines, respiratory disease, immunology, oncology, and infectious disease.

• SynagisMonoclonal antibody

  Synagis is the brand name for palivizumab, a monoclonal antibody used to help prevent serious respiratory syncytial virus infection in certain high-risk infants and young children. It became MedImmune's leading commercial product and represented the company's principal source of revenue during the mid-2000s.

• FluMistInfluenza vaccine2004

  FluMist is a live attenuated influenza vaccine administered as a nasal spray. MedImmune obtained the product through its 2002 acquisition of Aviron, launched it commercially in 2004, and developed later formulations and indications to address limitations associated with the original frozen presentation and restricted initial age range.

• DurvalumabOncology biologic

  Durvalumab was an anti-PD-L1 antibody in MedImmune's oncology development portfolio. It later became associated with AstraZeneca's oncology business and is marketed by AstraZeneca under the Imfinzi brand.

• NirsevimabRespiratory virus antibody

  Nirsevimab was an RSV-directed antibody included in MedImmune's development pipeline. The program was developed with Sanofi and subsequently became part of AstraZeneca's respiratory and infectious-disease portfolio.

• Moxetumomab pasudotoxOncology biologic

  Moxetumomab pasudotox was an anti-CD22 antibody-based therapy listed among MedImmune's late-stage development programs for cancer. The program illustrates the organization's focus on targeted biologics rather than only vaccines and respiratory products.

• BenralizumabRespiratory biologic

  Benralizumab is an anti-IL-5 receptor biologic developed for eosinophil-driven respiratory disease, including severe asthma. It was one of MedImmune's principal respiratory development programs and later became an AstraZeneca product under the Fasenra brand.

• 2009H1N1 influenza response

  United States

  MedImmune worked with the U.S. Department of Health and Human Services to continue seasonal FluMist production and develop a vaccine specifically targeting the novel H1N1 influenza strain during the 2009 outbreak.

  Outcome. The FDA approved MedImmune's intranasal H1N1 vaccine in September 2009.

  Source

• 2019Retire the MedImmune brandStrategy

  AstraZeneca had operated MedImmune as part of its broader biologics organization after the 2007 acquisition.

  What changed. AstraZeneca announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca.

  Aftermath. MedImmune ceased to function as a standalone public-facing brand, while its activities were represented within AstraZeneca.

  Source
• 2007AstraZeneca acquires MedImmuneM&A

  AstraZeneca wanted to strengthen its biologics research and development capabilities and broaden its pipeline.

  What changed. AstraZeneca agreed to an all-cash purchase at $58 per share and completed the acquisition in June 2007.

  Aftermath. MedImmune was combined with Cambridge Antibody Technology and operated as AstraZeneca's biologics organization before its branding was later retired.

  Reported transaction value. Approximately $15.2 billion (2007)

  Source
• 2002Acquire AvironM&A

  MedImmune sought to expand its vaccine portfolio and obtain Aviron's intranasal influenza-vaccine technology.

  What changed. MedImmune acquired Aviron for approximately $1.5 billion and added FluMist to its product portfolio.

  Aftermath. FluMist became one of MedImmune's best-known products and a major part of its respiratory-vaccine business.

  Reported acquisition value. $1.5 billion (2002)

  Source

• 2019AstraZeneca retires the MedImmune name

  AstraZeneca announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca.

  Other
  Source
• 2009MedImmune receives HHS H1N1 vaccine contract

  The U.S. Department of Health and Human Services awarded MedImmune a reported $90 million contract related to seasonal FluMist production and development of a novel H1N1 vaccine.

  Other
  Source
• 2009FDA approves MedImmune intranasal H1N1 vaccine

  The U.S. FDA approved MedImmune's intranasal vaccine for the novel H1N1 influenza strain.

  Product launchRegulation
  Source
• 2007AstraZeneca agrees to acquire MedImmune

  AstraZeneca announced an all-cash agreement to acquire MedImmune at $58 per share, with an announced transaction value of about $15.2 billion.

  M&A
  Source
• 2007AstraZeneca completes MedImmune acquisition

  AstraZeneca completed its purchase of MedImmune and incorporated the company into its biologics organization.

  M&A
  Source

1. MedImmune